AR105223A1 - Compuestos químicos - Google Patents
Compuestos químicosInfo
- Publication number
- AR105223A1 AR105223A1 ARP160100159A ARP160100159A AR105223A1 AR 105223 A1 AR105223 A1 AR 105223A1 AR P160100159 A ARP160100159 A AR P160100159A AR P160100159 A ARP160100159 A AR P160100159A AR 105223 A1 AR105223 A1 AR 105223A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticles
- sugar
- compositions
- polymers
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Manufacturing & Machinery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Nanopartículas que comprenden un poli(b-amino-éster) modificado en el extremo y un aditivo que es un azúcar o un derivado de azúcar, como ser un azúcar, un alcohol de azúcar o quitosano. Las nanopartículas pueden ser empleadas en cualquier campo en el que los polímeros resulten de utilidad, incluso en el campo de la medicina, en particular para la administración de fármacos. Los polímeros resultan útiles para la administración de un polinucleótido como ser ADN, ARN o siARN, una molécula pequeña cuna proteína. Composiciones que comprenden dichas nanoparticulas y un agente activo, métodos para la preparación de dichas nanopartículas, dichas nanopartículas y composiciones para ser empleadas en medicina, y métodos in vitro que utilizan dichas nanopartículas y composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1501025.9A GB201501025D0 (en) | 2015-01-21 | 2015-01-21 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105223A1 true AR105223A1 (es) | 2017-09-20 |
Family
ID=52630915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100159A AR105223A1 (es) | 2015-01-21 | 2016-01-21 | Compuestos químicos |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180000968A1 (es) |
EP (1) | EP3247338A1 (es) |
AR (1) | AR105223A1 (es) |
GB (1) | GB201501025D0 (es) |
TW (1) | TW201632206A (es) |
WO (1) | WO2016116887A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019213290A1 (en) | 2018-01-17 | 2020-08-06 | Ixaka France SAS | Polymer-encapsulated viral vectors for genetic therapy |
EP3969166A1 (fr) | 2019-05-16 | 2022-03-23 | Gem Innov | Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues |
AU2020349085A1 (en) | 2019-09-21 | 2022-04-28 | Ixaka France | DMSO-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems |
CN115298315A (zh) | 2019-11-15 | 2022-11-04 | 艾夏卡法国有限公司 | 用于体内基因治疗的聚合物封装病毒载体 |
MX2022014480A (es) | 2020-05-19 | 2022-12-13 | Ixaka France | Secuencias de promotor para la expresion in vitro e in vivo de productos de terapia genica en celulas cd3+. |
CN111944845B (zh) * | 2020-07-30 | 2022-06-07 | 珠海舒桐医疗科技有限公司 | 靶向敲除人乳头瘤病毒或疱疹病毒关键基因的复合纳米粒的制备 |
EP4166594A1 (en) * | 2021-10-14 | 2023-04-19 | Institut Químic de Sarrià CETS Fundació Privada | Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8257740B1 (en) * | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
WO2008109806A2 (en) * | 2007-03-08 | 2008-09-12 | Massachusetts Institute Of Technology | Electrostatic coating of particles for drug delivery |
GB201304245D0 (en) * | 2013-03-08 | 2013-04-24 | Inst Quimic De Sarria | Chemical compounds |
US20170348402A1 (en) * | 2014-07-30 | 2017-12-07 | The Research Foundation For The State University Of New York | System and method for delivering genetic material or protein to cells |
-
2015
- 2015-01-21 GB GBGB1501025.9A patent/GB201501025D0/en not_active Ceased
-
2016
- 2016-01-21 EP EP16702987.5A patent/EP3247338A1/en not_active Withdrawn
- 2016-01-21 TW TW105101945A patent/TW201632206A/zh unknown
- 2016-01-21 AR ARP160100159A patent/AR105223A1/es unknown
- 2016-01-21 US US15/545,421 patent/US20180000968A1/en not_active Abandoned
- 2016-01-21 WO PCT/IB2016/050299 patent/WO2016116887A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016116887A1 (en) | 2016-07-28 |
GB201501025D0 (en) | 2015-03-04 |
TW201632206A (zh) | 2016-09-16 |
US20180000968A1 (en) | 2018-01-04 |
EP3247338A1 (en) | 2017-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105223A1 (es) | Compuestos químicos | |
AR095081A1 (es) | Compuestos químicos | |
MX2021001118A (es) | Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa. | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
MX2017004306A (es) | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. | |
MX2015012433A (es) | Matriz de microestructura para suministro de agentes activos. | |
GT201200069A (es) | Formulaciones farmacéuticas muy concentradas | |
ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
CR20150604A (es) | Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos | |
CR20140475A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
EP4360621A3 (en) | Formulations of bendamustine | |
CY1120488T1 (el) | Υγρη φαρμακευτικη συνθεση | |
ECSP17085443A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma | |
MX2016012319A (es) | Formulaciones antihelminticas veterinarias estables. | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2012003209A1 (es) | Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. | |
MX2021002633A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
BR112018010400A2 (pt) | ?formulação de uma proteína, e, método para preparação de uma formulação de uma proteína? | |
BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
AR110595A1 (es) | Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos | |
CL2015003702A1 (es) | Formulación farmacéutica en forma de micropartículas estériles, que comprenden como agente activo rhein, y copolímeros del ácido láctico y glicólico (plga). proceso de elaboración y uso en pacientes que presentan patologías articulares. | |
CO2018002575A2 (es) | Composición de estabilidad mejorada de etanercept |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |